Can Targeted Steroid Use Transform TB Treatment?

Synopsis
Key Takeaways
- Targeted steroid use can boost macrophage function against TB.
- Dexamethasone reduces inflammation while supporting immune response.
- Macrophages treated with dexamethasone showed increased survival rates during infection.
- Research advocates for steroids as an adjunct therapy in TB management.
- New insights could redefine treatment approaches for TB.
New Delhi, Oct 11 (NationPress) Utilizing steroids in patient treatment may present a universal complementary approach to combat tuberculosis (TB) -- impacting over 10 million individuals globally each year, as per a recent study.
The research, featured in the journal Scientific Reports, revealed that the strategic application of steroids boosts the functionality of immune cells known as macrophages, enhancing their ability to eliminate mycobacteria while reducing inflammatory damage pathways.
Although steroids such as dexamethasone are administered in specific TB instances (e.g., TB meningitis), their effects on immune cells remain inadequately understood.
Dexamethasone, a powerful glucocorticoid, lowers glycolysis levels in human lung and blood-derived macrophages, thereby decreasing cellular energy availability.
The study indicated that dexamethasone also curtailed the synthesis of both pro- and anti-inflammatory cytokines. While this limitation can be beneficial for immunity, it may also help mitigate damage from excessive inflammation.
"In clinical practice, steroids are often the most underutilized adjunctive therapy for TB. We frequently depend on steroids to manage inflammation in tuberculosis, particularly in severe cases like TB meningitis,” commented Prof. Joseph Keane, Professor of Medicine at Trinity College Dublin in Ireland.
"What's encouraging from this research is that dexamethasone not only moderates inflammation but also seems to bolster the macrophage's ability to combat infection. This study offers new insights to redefine steroid application in TB management -- targeting inflammation without undermining antimicrobial defense,” he added.
The researchers examined macrophages sourced from healthy volunteers' blood or isolated from lung fluid donated by patients undergoing routine bronchoscopies.
By infecting these macrophages with Mtb in laboratory settings, the scientists could investigate and comprehend how dexamethasone influences the immune response that protects the lungs during infection.
Mtb-infected macrophages exhibited increased survival rates when treated with dexamethasone, suggesting that it could shield macrophages from dying due to the adverse effects of infection or harmful immune reactions.
Dexamethasone also diminishes bacterial load in infected macrophages, with the team discovering that this effect is at least partially mediated through autophagy and phagosomal acidification. Dexamethasone enhances macrophages' capability to degrade and eliminate bacteria, aiding in overcoming Mtb infection.
The results advocate for steroid use as an additional treatment alongside existing antimicrobial therapies in TB management, particularly in instances of excessive inflammation.